Pelthos Therapeutics
PTHS
9 hedge funds and large institutions have $846K invested in Pelthos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
5,178% more capital invested
Capital invested by funds: $16K → $846K (+$830K)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
125% more funds holding
Funds holding: 4 → 9 (+5)
0.94% more ownership
Funds ownership: 0.04% → 0.98% (+0.94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$755K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$224K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.97K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$9.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| $626K | +$755K | +44,085 | New |
|
|
BFM
2
Boothbay Fund Management
New York
| $186K | +$224K | +13,075 | New |
|
3
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| $14.8K | – | – | – |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $14.3K | +$17.2K | +1,007 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.64K | +$3.97K | +232 | +928% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1.41K | +$1.71K | +100 | New |
|
|
TCM
7
Tradewinds Capital Management
Bellingham,
Washington
| $284 | +$342 | +20 | New |
|
8
Barclays
London,
United Kingdom
| $77 | +$86 | +5 | New |
|
9
Bank of America
Charlotte,
North Carolina
| $17 | – | – | – |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$9.2K | -1,435 | Closed |
|
PTHS Hedge Fund Activity: Q1 2025 in Review
9 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q1 2025, worth a combined $846K — up 5,178% from $16K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PTHS positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $755K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $9.2K sold.
- 9 institutional investors held Pelthos Therapeutics (PTHS) as of Q1 2025, up from 4 in Q4 2024.
- Funds reported $846K of Pelthos Therapeutics stock for Q1 2025, up 5,178% quarter-over-quarter.
- 6 funds opened new Pelthos Therapeutics positions in Q1 2025 and 1 closed out, a net change of +5 holders.
- The largest Pelthos Therapeutics buyer in Q1 2025 was Ikarian Capital, an estimated $755K added.
- The largest Pelthos Therapeutics seller in Q1 2025 was Two Sigma Securities, an estimated $9.2K sold.
Based on aggregated 13F filings for Q1 2025.